On November 21, 2022, clinical stage biotechnology company Tenaya Therapeutics announced the closing of a public stock offering, which raised approximately $75 million. Wilson Sonsini Goodrich & Rosati advised Tenaya on the transaction.

The company sold 22,613,307 million shares at a price of $2.60 and pre-funded warrants allowing some investors to buy an additional 6,236,693 shares at a price of $2.599. Underwriters will have an option to purchase an additional 4,327,500 shares. South San Francisco-based Tenaya was founded by cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center. The company is focusing on developing therapies for rare genetic disorders and for heart conditions using gene therapy, cellular regeneration and precise medicine.

The Wilson Sonsini team that advised Tenaya on the transaction included:

Corporate
Jennifer Knapp
Emily Coskey
Eric Abram
Joshua Deal
Tamara Labanowski
Erica Wolfe Heinz

Patents and Innovation
Michael Hostetler
Uale Taotafa
Derrick Rowe

For more information, please see Tenaya’s press release.